Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer

Prospective Pilot Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer

The death of prostate cancer patients is mainly due to metastatic castration-resistant prostate cancer. Though some new therapies has been tried to prolong the life-span of mCRPC patients, a dilemma was encountered for the drug-resistance. The PSMA RLT has been tested its efficacy and safety for the therapy of these patients. In our clinical trial, a new PSMA ligand will been used to be labeled with Ac225. This will be a prospective pilot clinical trial. 20 mCRPC patients who was incapable of 2rd ADT or chemotherapy will be recruited in this clinical tiral. The efficacy and safety of 225Ac-PSMA will be evaluated after the administration.

Inclusion Criteria:

• Pathologically confirmed prostatic adenocarcinoma.
• Clinically or imaging confirmed metastatic castration resistant prostate cancer.
• Conventional treatment failure or not available.
• PSMA avid of lesions confirmed by PSMA PET/CT.
• Hematopoietic function, kidney and liver function is normal.
• Can follow the study plan and can timely follow-up.
• Agree to sign the informed consent.

Exclusion Criteria:

• Pathological types other than the prostatic adenocarcinoma of prostate cancer.
• Not PSMA avid of lesions confirmed by PSMA PET/CT.
• Concurrent with other uncontrolled malignant tumours or five years, except for carcinoma in situ.
• Concomitant diseases are not suitable for radioactive therapy.
• Other conditions (religion, psychology, etc.) affect the informed consent, research plan, or not compliant of follow-up schedule.